ReNew Publishes First Annual Integrated Report Aligned With International Integrated Reporting Standards
5.8.2024 16:56:00 EEST | Business Wire | Press release
ReNew Energy Global Plc ("ReNew") (NASDAQ: RNW), India’s leading decarbonization solutions provider, released its first Annual Integrated Report (for FY 2023-24) today. The report titled ‘Innovating Clean Energy Solutions’ reinforces ReNew’s position as a global pioneer in the clean energy landscape while integrating sustainability, nurturing equity, and embodying responsible stewardship.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240805395803/en/
From left to right: Vaishali Nigam Sinha, Co-Founder & Chairperson, Sustainability, ReNew; Sir Sumantra Chakrabarti, Chairperson, ESG Committee and Independent Director, ReNew; and Sumant Sinha, Founder, Chairman & CEO, ReNew at ReNew Hub on Friday, 2 August, 2024 (Photo: Business Wire)
The report demonstrates ReNew’s commitment to ensure its disclosures go above and beyond any single geographical reporting standard and to continue to advance towards enhanced global reporting standards. ReNew has, for the first time, aligned with the EU Taxonomy and reports 97.79% of its capital expenditure aligned with it. The taxonomy is a classification system that lays out the criteria for economic activities which are aligned with a net-zero trajectory by 2050. This strategic move bolsters sustainable investment and elevates the transparency of its economic activities, in harmony with climate objectives and broader environmental goals.
Sumant Sinha, Founder, Chairman, and CEO, ReNew, said: “As a pioneer in India’s renewable energy sector, we are committed to strategically expanding our footprint in the Indian market with targeted investments in select emerging markets globally. As we look ahead, we envision doubling our aggregate portfolio to ~21 GW in the next five years. Our first Annual Integrated Report reflects our commitment to scale up renewable energy projects and meet the growing demand for clean and sustainable power solutions in an environmentally and socially responsible manner.”
ReNew also undertook its first Double Materiality Assessment in FY 2023-24, a notable responsibility in its journey towards sustainable excellence. Double materiality is an impact assessment method which shows an organization’s actual and potential adverse impacts on people, society and the environment from both a financial and non-financial perspective.
As outlined in the report, FY 2023-24 was marked by significant milestones for ReNew. The Company crossed the mark of 10 GW set up cumulative capacity and recorded a net profit of INR 4,147 million (US$ 50 million).
Vaishali Nigam Sinha, Co-Founder and Chairperson - Sustainability, ReNew, said:“As the world inches closer to the critical 1.5 degrees Celsius climate threshold, we, at ReNew, are playing a pivotal role in enabling India’s low carbon development pathways. We have committed to net-zero goals by 2040, validated by the Science Based Targets initiative (SBTi), which makes us one of the first pure-play renewable energy companies to receive this recognition.”
Solidifying its position as a leading clean energy player, ReNew reported 16 million tonnes of CO2e mitigation, accounting for ~0.6% of India’s total carbon emissions. Demonstrating tangible progress towards its own net-zero commitment by 2040, the Company witnessed a ~10% reduction in Scope 1 and 2 emissions for FY 2023-24 compared to the baseline year FY 2021-22. ReNew also achieved carbon neutrality for Scope 1 and Scope 2 emissions for the fourth consecutive year. Scope 1 are direct emissions owned or controlled by a company, whereas Scope 2 are indirect emissions from the generation of purchased electricity consumed by a company.
ReNew has reinstated its commitment to building an environment that prioritizes employee safety and inclusivity. The Company was certified a ‘Great Place to Work’ for the fourth consecutive year and recorded an employee gender diversity rate of ~14%, with ~10% women representation in science, technology, engineering, and maths (STEM) roles, far surpassing industry standards.
ReNew’s Annual Integrated Report FY 2023-24 is available here.
Note to Editors:
About the Report:
The Annual Integrated Report FY 2023-24 was crafted in alignment with the International Integrated Reporting Council (IIRC) framework established by the International Financial Reporting Standards (IFRS) Foundation. In preparing this report, ReNew has also referenced the Global Reporting Initiative (GRI) Standards 2021, United Nations Sustainable Development Goals (UN SDGs), Sustainability Accounting Standards Board (SASB), United Nations Global Compact (UNGC), United Nations Women’s Empowerment Principles (UNWEP), International Finance Corporation (IFC) Standards, Equator Principles (EP) and Task Force on Climate-related Financial Disclosures (TCFD). The Double Materiality methodology was based on the European Financial Reporting Advisory Group (EFRAG) under the Corporate Sustainability Reporting Directive (CSRD) and aligns with the requirements of IFRS standards. The non-financial sustainability information presented in the Report is externally assured by Ernst and Young Associates LLP. The financial statements presented in the Report are audited by S.R. Batliboi & Co. LLP, a network firm of Ernst & Young.
About ReNew
ReNew is a leading decarbonization solutions company listed on Nasdaq (NASDAQ: RNW). ReNew's clean energy contracted portfolio of ~15.6 GW as of May 31, 2024, is one of the largest globally. In addition to being a major independent power producer in India, we provide end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. For more information, visit www.renew.com and follow us on LinkedIn, Facebook, Twitter and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240805395803/en/
Contacts
Press Enquiries
Shilpa Narani | shilpa.narani@renew.com
Investor Enquiries
Nathan Judge, Anunay Shahi, Nitin Vaid | ir@renew.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom